HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong-Wan Kim, Melissa L. Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti Patel, Egbert Smit, Karen L. Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W. Sternberg, Dalila Sellami, Pasi A. Jänne

Open source

DOI
10.1200/jco.23.01476
Published
2023-12-10
Container
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1200/jco.23.01476,
  title = {HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy},
  author = {Helena A. Yu and Yasushi Goto and Hidetoshi Hayashi and Enriqueta Felip and James Chih-Hsin Yang and Martin Reck and Kiyotaka Yoh and Se-Hoon Lee and Luis Paz-Ares and Benjamin Besse and Paolo Bironzo and Dong-Wan Kim and Melissa L. Johnson and Yi-Long Wu and Thomas John and Steven Kao and Toshiyuki Kozuki and Erminia Massarelli and Jyoti Patel and Egbert Smit and Karen L. Reckamp and Qian Dong and Pomy Shrestha and Pang-Dian Fan and Parul Patel and Andrea Sporchia and David W. Sternberg and Dalila Sellami and Pasi A. Jänne},
  year = {2023},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.23.01476},
  url = {https://doi.org/10.1200/jco.23.01476}
}

RIS

TY  - JOUR
TI  - HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
AU  - Helena A. Yu
AU  - Yasushi Goto
AU  - Hidetoshi Hayashi
AU  - Enriqueta Felip
AU  - James Chih-Hsin Yang
AU  - Martin Reck
AU  - Kiyotaka Yoh
AU  - Se-Hoon Lee
AU  - Luis Paz-Ares
AU  - Benjamin Besse
AU  - Paolo Bironzo
AU  - Dong-Wan Kim
AU  - Melissa L. Johnson
AU  - Yi-Long Wu
AU  - Thomas John
AU  - Steven Kao
AU  - Toshiyuki Kozuki
AU  - Erminia Massarelli
AU  - Jyoti Patel
AU  - Egbert Smit
AU  - Karen L. Reckamp
AU  - Qian Dong
AU  - Pomy Shrestha
AU  - Pang-Dian Fan
AU  - Parul Patel
AU  - Andrea Sporchia
AU  - David W. Sternberg
AU  - Dalila Sellami
AU  - Pasi A. Jänne
PY  - 2023
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.23.01476
UR  - https://doi.org/10.1200/jco.23.01476
ER  - 

APA

Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Yang, J. C., Reck, M., Yoh, K., Lee, S., Paz-Ares, L., Besse, B., Bironzo, P., Kim, D., Johnson, M. L., Wu, Y., John, T., Kao, S., Kozuki, T., Massarelli, E., Patel, J., Smit, E., Reckamp, K. L., Dong, Q., Shrestha, P., Fan, P., Patel, P., Sporchia, A., Sternberg, D. W., Sellami, D., & Jänne, P. A. (2023). HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01476

Source records